Latest Healthcare News

Opyl Limited has successfully raised $1.5 million through an oversubscribed placement to accelerate the growth of its AI-driven clinical trial platform, Trialkey. The capital injection underscores strong investor confidence as the company prepares for a pivotal expansion phase.

Oncosil Medical Ltd has announced a significant 400-for-1 security consolidation affecting shares, options, and performance rights, with shareholder approval scheduled for late May 2025.

Nuchev Limited has entered an exclusive sales agency agreement with Brauer Natural Medicines and H&S Brand Corporation, expanding its footprint in Australia's natural and complementary medicines sector. The deal covers key brands including Brauer, Skin Physics, and Rapid Loss, with potential for broader ANZ distribution.

Healius Limited has completed the $822 million cash sale of Lumus Imaging to Affinity Equity Partners, setting the stage for a strategic refocus on pathology and a substantial special dividend payout.

Anagenics Limited reported a cash outflow of $424K for Q3 2025 but maintains robust liquidity with $1.48 million in available funding, supported by a mix of secured and unsecured loans.

BlinkLab Limited has raised A$7.66 million through a well-supported placement to accelerate FDA regulatory trials for its autism and ADHD diagnostic platforms, leveraging its innovative smartphone-based technology.

Dimerix Limited has announced a US licensing transaction for its Phase 3 asset DMX-200 targeting FSGS, alongside progress updates on its clinical trial. The move underscores the company’s push to address a rare kidney disease with no approved therapies.

Imricor Medical Systems has initiated its first MRI-guided atrial flutter ablation procedures at Semmelweis University in Budapest, marking a significant expansion of its real-time MRI technology in Europe.

Anatara Lifesciences has obtained a $400,000 loan advance from a major shareholder group against its estimated R&D tax refund for the first half of FY2025, providing crucial funding to support ongoing clinical trials and product development without immediate capital raising.

Amcor has completed its transformative merger with Berry Global ahead of schedule, reporting steady Q3 fiscal 2025 results and setting ambitious synergy targets that promise to reshape its growth trajectory.

AdAlta Limited has made significant progress in its 'East to West' cellular immunotherapy strategy by executing three CAR-T term sheets and completing technical due diligence, while implementing cost-cutting measures and seeking new capital amid a tough financing environment.

Memphasys Limited has completed a pivotal Phase III trial confirming its Felix™ System as best-in-class for sperm separation, while advancing regulatory and commercial efforts in China and Brazil supported by fresh capital.